Peptide Based Metabolic Disorders Therapeutics Market Report 2025

This Peptide Based Metabolic Disorders Therapeutics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $29.89 billion in 2024 to $34.4 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to the increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditure, a growing aging population, an expanding biopharmaceutical sector, regulatory approvals for new therapies, and increasing awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $59.85 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to the development of novel peptide analogs, rising R&D investments in metabolic disorders, adoption of precision medicine approaches, expansion of emerging markets, collaborations and partnerships in drug development, advancements in delivery technologies, and focus on patient-centric therapies. Major trends in the forecast period include the application of artificial intelligence in drug discovery, the growth of personalized therapies, the utilization of CRISPR/Cas9 for genetic therapies, the integration of wearable devices for patient monitoring, the development of oral peptide formulations, the rise of digital therapeutics in disease management, and the expansion of biobanking for personalized treatments.

The increasing prevalence of obesity is expected to drive the growth of the peptide-based metabolic disorders therapeutic market. Obesity is a medical condition characterized by excessive body fat accumulation, which poses significant health risks. The rising incidence of obesity is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, and environmental influences that encourage calorie-rich diets and physical inactivity. Peptide-based therapeutics for metabolic disorders focus on managing conditions like obesity by using peptides to regulate metabolic functions, enhance insulin sensitivity, and control appetite, thereby improving patient outcomes and reducing the long-term health risks associated with chronic metabolic conditions. For instance, in April 2024, the British Diabetic Association, a UK-based healthcare charity, reported that 4.4 million people in the UK are living with diabetes, with an additional 1.2 million potentially undiagnosed with type 2 diabetes. The 2022-2023 registration figures show an increase of 167,822 compared to the previous year. Consequently, the rising prevalence of obesity is propelling the growth of the peptide-based metabolic disorders therapeutics market.

Leading companies in the peptide-based metabolic disorders therapeutic market are focusing on developing innovative treatments, such as biosimilar versions of peptide-based anti-diabetic drugs, to address unmet medical needs and broaden treatment options for patients. Peptide-based anti-diabetic biosimilars replicate existing peptide therapies for diabetes, offering similar efficacy and safety profiles at potentially lower costs through competitive pricing strategies. For instance, Glenmark Pharmaceuticals Ltd., based in India, launched Lirafit in January 2024, a biosimilar of Liraglutide, a popular anti-diabetic medication belonging to the GLP-1 receptor agonist class. These drugs mimic the action of the natural GLP-1 hormone, crucial for regulating blood sugar levels. Clinical trials have demonstrated Lirafit's effectiveness in improving glycemic control, promoting weight loss, and enhancing cardiovascular safety, which are critical benefits in managing diabetes, obesity, and related cardiovascular conditions.

In December 2023, Roche Holding AG, a healthcare company based in Switzerland, completed the acquisition of Carmot Therapeutics Inc. for $2.7 billion. Through this transaction, Roche secures access to Carmot's clinical-stage incretins, including CT-388, a dual GLP-1/GIP receptor agonist currently in Phase 2 trials. This compound holds promise for treating obesity in both diabetic and non-diabetic patients. Carmot Therapeutics Inc., a clinical-stage biotechnology firm, focuses on developing peptide-based therapeutics primarily aimed at metabolic disorders such as diabetes and obesity.

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group.

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide based metabolic disorders therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Peptide-based therapeutics for metabolic disorders are pharmaceutical treatments derived from short chains of amino acids, known as peptides. These therapies target and modulate biological pathways involved in conditions such as diabetes, obesity, and related disorders. Their primary objectives include regulating hormone levels, improving insulin sensitivity, managing appetite, and controlling glucose metabolism, all aimed at enhancing patient outcomes and quality of life.

Key drugs in the peptide-based treatment of metabolic disorders include liraglutide, exenatide, and others. Liraglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of natural GLP-1. This hormone regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion. Liraglutide is utilized in the treatment of conditions such as lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, among others. Distribution channels for these therapies include hospital pharmacies, retail pharmacies, and online pharmacies.

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports that provides peptide based metabolic disorders therapeutics market statistics, including peptide based metabolic disorders therapeutics industry global market size, regional shares, competitors with an peptide based metabolic disorders therapeutics market share, detailed peptide based metabolic disorders therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. This peptide based metabolic disorders therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.